Hennion & Walsh Asset Management, Inc. Mirum Pharmaceuticals, Inc. Call Options Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding MIRM
# of Institutions
230Shares Held
56.1MCall Options Held
25.3KPut Options Held
98.9K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.8MShares$504 Million18.24% of portfolio
-
Janus Henderson Group PLC London, X05.24MShares$388 Million0.14% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$240 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA2.76MShares$205 Million5.52% of portfolio
-
Eventide Asset Management, LLC Boston, MA2.64MShares$196 Million2.55% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $2.73B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...